6 Regulatory Deadlines Ketamine Clinics Should Have on the Calendar
The next fifteen months are crowded with federal and state deadlines for ketamine clinics. Some are comment windows that close quietly. Others decide whether a prescription written next January is legal. Here are six dates worth putting on the practice calendar now, in order, with what each one means.
Every deadline on this list lands on a clinic’s overhead. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Date | Deadline | Who it affects |
|---|---|---|
| October 5, 2026 | FDA psychedelics hearing docket closes | Any clinic with a view on training, access or data |
| October 15, 2026 | ARPA-H ibogaine trial summaries due | Clinics with research partners |
| November 2026 | DEA telemedicine final rule expected | Every clinic that prescribes by telehealth |
| December 31, 2026 | DEA telehealth flexibilities expire | Every clinic that prescribes by telehealth |
| First half of 2027 | Compass launch target for psilocybin | Spravato and interventional psychiatry sites |
| December 31, 2027 | Medicare telehealth and New Mexico deadlines | Medicare billers and New Mexico clinicians |
1. October 5: FDA’s Psychedelics Docket Closes
FDA held its Part 15 public hearing on psychedelic drugs on September 14. The Federal Register notice keeps the written docket, FDA-2026-N-7542, open until 11:59 p.m. Eastern on October 5.
The hearing covered four areas. Provider training and credentialing, patient safety, access, and data collection standards. Every one of them touches how clinics would deliver an approved psychedelic.
About 80 people spoke for two minutes each. A short written comment from an operator describing monitoring, staffing and chair time adds practical detail to the record. We covered what the hearing was really about.
2. October 15: ARPA-H Ibogaine Trial Summaries Due
ARPA-H’s ASCENT-IBO program will fund Phase 1 and 2 trials of ibogaine for opioid use disorder. Solution summaries are due October 15 at 9:00 p.m. Eastern.
Most clinics will not lead a proposal. ARPA-H does anticipate teaming across academia, industry and government, and trials need clinical sites and staff who can monitor patients.
Clinics with an academic partner or an addiction medicine program should ask that partner now. Our ASCENT-IBO breakdown covers what the program funds and what it leaves out.
3. November: DEA’s Telemedicine Final Rule Is Expected
The DEA has spent years on a permanent framework for prescribing controlled substances by telemedicine. The special registration rule is the centerpiece.
According to the Alliance for Connected Care, the Justice Department forecasts the final rule for November 2026. Forecasts slip, so treat that month as a target.
The proposed version would add requirements for PDMP checks, audio and video visits and identity verification. It also covers data reporting to the DEA and record retention. Whatever is finalized will need a compliance plan within weeks.
4. December 31: DEA Telehealth Flexibilities Expire
This is the date that matters most for any clinic prescribing ketamine without a prior in-person exam. The fourth temporary extension of the DEA’s telemedicine flexibilities runs through December 31, 2026.
If a final rule or another extension does not arrive first, the stricter default rules return on January 1. The flexibilities have now been extended four times, and each extension has been labeled temporary.
The practical step is an inventory. List every workflow where a controlled substance prescription happens without an in-person visit. Our telehealth deadline guide walks through that audit, and the DEA audit readiness tool helps with records.
5. First Half of 2027: The Psilocybin Launch Target
This one is a company target, not a regulatory date. Compass Pathways expects to finish its rolling application for COMP360 by the end of 2026. It targets a launch in the first half of 2027.
That timeline depends on FDA approval, DEA rescheduling and state action. Virginia has already passed a trigger law that reschedules an approved psilocybin formulation once FDA acts.
Compass has said it has collaborations with more than 1,000 sites that already deliver Spravato. We covered why Spravato clinics are first in line, and what longer sessions do to chair economics.
6. December 31, 2027: Two Deadlines on One Day
The first is federal. CMS says in its 2026 telehealth FAQ that Medicare telehealth flexibilities run through December 31, 2027.
That includes the delay on the in-person visit requirement for mental health telehealth. After that date, Medicare requires an in-person visit within six months before the first telehealth service. Established patients then need one in-person visit every 12 months.
That matters most for Spravato and psychiatry practices billing Medicare for telehealth follow ups. Tracking in-person visit dates by patient is worth building well before the cutoff.
The second is New Mexico. Its Medical Psilocybin Act sets a statutory deadline of December 31, 2027 for the state’s program. The Department of Health is aiming to serve first patients by the end of 2026.
We think the earlier target looks unlikely, for reasons laid out in our New Mexico permit coverage. Clinicians there should plan against the statutory date.
The One Without a Date: Texas
Texas clinics have a deadline coming that nobody can put on a calendar yet. The Texas Medical Board published its latest ketamine therapy rules in the July 10 Texas Register.
The board says a public hearing will be held at a later date. No adoption vote or effective date has been set. We have tracked each revision in our Texas rules coverage.
Texas operators should watch the board’s rule changes page for a hearing notice. That hearing may be the last chance to comment.
How to Use This List
Put all six dates on the practice calendar with a named owner for each. Most will need a decision a month ahead, not the week of.
Four of the six land before the end of this year. State rules vary on top of all of this. Our state regulatory navigator covers the rules where a clinic operates.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal advice. Dates reflect official sources as of September 22, 2026 and can change. Confirm with counsel before acting.
